These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 1886423

  • 1. Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.
    Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Cook P, Puccio C, Baskind P, Arnold P, Razis ED.
    Leukemia; 1991 Aug; 5(8):712-4. PubMed ID: 1886423
    [Abstract] [Full Text] [Related]

  • 2. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R, Lerede T, Buelli M, Borleri G, Bellavita P, Rambaldi A, Barbui T.
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P.
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [Abstract] [Full Text] [Related]

  • 4. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 5. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.
    Weiss M, Maslak P, Feldman E, Berman E, Bertino J, Gee T, Megherian L, Seiter K, Scheinberg D, Golde D.
    J Clin Oncol; 1996 Sep; 14(9):2480-5. PubMed ID: 8823326
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
    Brito-Babapulle F, Catovsky D, Slocombe G, Newland AC, Marcus RE, Goldman JM, Galton DA.
    Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
    [Abstract] [Full Text] [Related]

  • 7. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
    Hiddemann W, Büchner T, Heil G, Schumacher K, Diedrich H, Maschmeyer G, Ho AD, Planker M, Gerith-Stolzenburg S, Donhuijsen-Ant R.
    Leukemia; 1990 Sep; 4(9):637-40. PubMed ID: 2395383
    [Abstract] [Full Text] [Related]

  • 8. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z, Case DC, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K.
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S.
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [Abstract] [Full Text] [Related]

  • 10. Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
    Raanani P, Shpilberg O, Gillis S, Avigdor A, Hardan I, Berkowicz M, Sofer O, Lossos I, Chetrit A, Ben-Yehuda D, Ben-Bassat I.
    Leuk Res; 1999 Aug; 23(8):695-700. PubMed ID: 10456666
    [Abstract] [Full Text] [Related]

  • 11. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 12. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
    Al Bahar S, Pandita R, Bavishi K, Savani B.
    Neoplasma; 1999 Nov; 46(1):61-5. PubMed ID: 10355536
    [Abstract] [Full Text] [Related]

  • 13. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
    Karanes C, Kopecky KJ, Head DR, Grever MR, Hynes HE, Kraut EH, Vial RH, Lichtin A, Nand S, Samlowski WE, Appelbaum FR.
    Leuk Res; 1999 Sep; 23(9):787-94. PubMed ID: 10475617
    [Abstract] [Full Text] [Related]

  • 14. [Preliminary results of the treatment of acute leukemia with mitoxantrone].
    Rozmysłowicz T, Pałynyczko G, Mazur J, Konecki R, Apel D, Mariańska B, Maj S, Hołowiecki J, Rudzka E, Lawniczek T.
    Acta Haematol Pol; 1991 Sep; 22(1):69-81. PubMed ID: 1823970
    [Abstract] [Full Text] [Related]

  • 15. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
    Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE.
    Cancer; 2002 Aug 01; 95(3):581-7. PubMed ID: 12209751
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
    Daenen S, Löwenberg B, Sonneveld P, van Putten WL, Verhoef G, Verdonck LF, van Veldhoven M, Huijgens PC.
    Leukemia; 1994 Jan 01; 8(1):6-10. PubMed ID: 8289499
    [Abstract] [Full Text] [Related]

  • 17. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, Jakubas B, Palynyczko G, Lewandowski K, Dmoszynska A, Skotnicki A, Nowak K, Holowiecki J, Polish Adult Leukemia Group.
    Ann Hematol; 2006 Oct 01; 85(10):717-22. PubMed ID: 16832677
    [Abstract] [Full Text] [Related]

  • 18. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Oct 01; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 19. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R, Ho AD, Del Valle F, Fischer JT, Ehrhardt R, Döhner H, Witt B, Huberts H, Kaplan E, Hunstein W.
    Semin Oncol; 1993 Dec 01; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [Abstract] [Full Text] [Related]

  • 20. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
    He XY, Pohlman B, Lichtin A, Rybicki L, Kalaycio M.
    Leukemia; 2003 Jun 01; 17(6):1078-84. PubMed ID: 12764371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.